190 related articles for article (PubMed ID: 24720840)
1. An adjuvanted inactivated murine cytomegalovirus (MCMV) vaccine induces potent and long-term protective immunity against a lethal challenge with virulent MCMV.
Wang H; Yao Y; Huang C; Fu X; Chen Q; Zhang H; Chen J; Fang F; Xie Z; Chen Z
BMC Infect Dis; 2014 Apr; 14():195. PubMed ID: 24720840
[TBL] [Abstract][Full Text] [Related]
2. Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication.
Morello CS; Ye M; Spector DH
J Virol; 2002 May; 76(10):4822-35. PubMed ID: 11967299
[TBL] [Abstract][Full Text] [Related]
3. Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.
Morello CS; Ye M; Hung S; Kelley LA; Spector DH
J Virol; 2005 Jan; 79(1):159-75. PubMed ID: 15596812
[TBL] [Abstract][Full Text] [Related]
4. Comparison of multiple DNA vaccines for protection against cytomegalovirus infection in BALB/c mice.
Huang C; Wang H; Wu S; Chang H; Liu L; Peng B; Fang F; Chen Z
Virol J; 2014 Jun; 11():104. PubMed ID: 24898886
[TBL] [Abstract][Full Text] [Related]
5. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65).
Morello CS; Cranmer LD; Spector DH
J Virol; 2000 Apr; 74(8):3696-708. PubMed ID: 10729145
[TBL] [Abstract][Full Text] [Related]
6. Immunization with cytomegalovirus envelope glycoprotein M and glycoprotein N DNA vaccines can provide mice with complete protection against a lethal murine cytomegalovirus challenge.
Wang H; Yao Y; Huang C; Chen Q; Chen J; Chen Z
Virol Sin; 2013 Jun; 28(3):174-82. PubMed ID: 23715998
[TBL] [Abstract][Full Text] [Related]
7. Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus (MCMV) infection by using an attenuated MCMV mutant.
MacDonald MR; Li XY; Stenberg RM; Campbell AE; Virgin HW
J Virol; 1998 Jan; 72(1):442-51. PubMed ID: 9420244
[TBL] [Abstract][Full Text] [Related]
8. Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus.
Gopal IN; Quinn A; Henry SC; Hamilton JD; Staats HF; Frothingham R
Microbiol Immunol; 2005; 49(2):113-9. PubMed ID: 15722596
[TBL] [Abstract][Full Text] [Related]
9. Protective MCMV immunity by vaccination of the salivary gland via Wharton's duct: replication-deficient recombinant adenovirus expressing individual MCMV genes elicits protection similar to that of MCMV.
Liu G; Zhang F; Wang R; London L; London SD
FASEB J; 2014 Apr; 28(4):1698-710. PubMed ID: 24391133
[TBL] [Abstract][Full Text] [Related]
10. A Live Olfactory Mouse Cytomegalovirus Vaccine, Attenuated for Systemic Spread, Protects against Superinfection.
Farrell HE; Bruce K; Stevenson PG
J Virol; 2021 Oct; 95(21):e0126421. PubMed ID: 34431701
[TBL] [Abstract][Full Text] [Related]
11. Multiple epitopes in the murine cytomegalovirus early gene product M84 are efficiently presented in infected primary macrophages and contribute to strong CD8+-T-lymphocyte responses and protection following DNA immunization.
Ye M; Morello CS; Spector DH
J Virol; 2004 Oct; 78(20):11233-45. PubMed ID: 15452242
[TBL] [Abstract][Full Text] [Related]
12. Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge.
Ye M; Morello CS; Spector DH
J Virol; 2002 Mar; 76(5):2100-12. PubMed ID: 11836387
[TBL] [Abstract][Full Text] [Related]
13. Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy.
Cicin-Sain L; Bubić I; Schnee M; Ruzsics Z; Mohr C; Jonjić S; Koszinowski UH
J Virol; 2007 Dec; 81(24):13825-34. PubMed ID: 17913824
[TBL] [Abstract][Full Text] [Related]
14. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
[TBL] [Abstract][Full Text] [Related]
15. DNA immunization confers protection against murine cytomegalovirus infection.
González Armas JC; Morello CS; Cranmer LD; Spector DH
J Virol; 1996 Nov; 70(11):7921-8. PubMed ID: 8892915
[TBL] [Abstract][Full Text] [Related]
16. Pasteurella multocida inactivated with ferric chloride and adjuvanted with bacterial DNA is a potent and efficacious vaccine in Balb/c mice.
Homayoon M; Tahamtan Y; Kargar M; Hosseini SMH; Akhavan Sepahy A
J Med Microbiol; 2018 Sep; 67(9):1383-1390. PubMed ID: 30016232
[TBL] [Abstract][Full Text] [Related]
17. Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.
Wilson SR; Wilson JH; Buonocore L; Palin A; Rose JK; Reuter JD
Comp Med; 2008 Apr; 58(2):129-39. PubMed ID: 18524170
[TBL] [Abstract][Full Text] [Related]
18. High-frequency interferon-gamma-secreting splenocytes specific for murine cytomegalovirus immediate-early-1 (IE-1) peptide 168YPHFMPTNL176 are insufficient to provide complete protection from viral challenge.
Morley PJ; Ertl PF; Sweet C
J Med Virol; 2003 Feb; 69(2):240-50. PubMed ID: 12683414
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation.
Roback JD; Hossain MS; Lezhava L; Gorechlad JW; Alexander SA; Jaye DL; Mittelstaedt S; Talib S; Hearst JE; Hillyer CD; Waller EK
J Immunol; 2003 Dec; 171(11):6023-31. PubMed ID: 14634114
[TBL] [Abstract][Full Text] [Related]
20. Self HSP60 peptide serves as an immunogenic carrier for a CTL epitope against persistence of murine cytomegalovirus in the salivary gland.
Rouvio O; Dvorkin T; Amir-Kroll H; Atias D; Cohen IR; Rager-Zisman B; Porgador A
Vaccine; 2005 May; 23(27):3508-18. PubMed ID: 15855009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
